Medical affairs has evolved far beyond its traditional role as a scientific support function. As healthcare becomes increasingly data-driven, leaders are expected to navigate complex clinical evidence, business priorities, regulatory requirements, and patient outcomes simultaneously. According to Paul Mastoridis, Pharmaceutical and Device Executive and a global business process expert with more than 25 years of experience across drug development, medical devices, AI, and digital health, the leaders who succeed are distinguished by three capabilities: strategy, storytelling, and trust.
“Strategy is how you decide what evidence actually matters. Storytelling is how you make that evidence meaningful. And trust is the only currency that gets you invited into the conversations that shape decisions,” says Mastoridis. “You can hire writers, analysts, and agencies, but you can’t delegate judgment, narrative, or credibility.” His perspective is informed by a career spanning every phase of drug development, from clinical research and regulatory strategy to global medical affairs leadership, product launches, and patient-focused innovation. Across that journey, one lesson has remained constant: scientific expertise alone is not enough.
Turning Evidence Into Meaning
The healthcare industry generates vast amounts of clinical data, but data without context doesn’t change behavior. For medical affairs leaders, the challenge is translating evidence into practical relevance for physicians, payers, and patients. “A busy clinician doesn’t want a data dump,” he says. “They want to know what changes tomorrow morning at 8 a.m. when my first patient walks in.” The questions physicians care about are patient-centric: Who is the right patient? Who is the wrong patient? What problem does this solve that nothing else solves? “If you can answer those three things clearly, then the science lands,” Mastoridis says. “If you can’t, it doesn’t matter how beautiful your Kaplan-Meier curves are.
This ability to translate complexity into clarity has become increasingly important as therapies, devices, and digital health solutions become more sophisticated. Scientific rigor remains essential, but meaningful communication is what allows evidence to influence real-world decision making.
Storytelling Builds Credibility
“The storytelling is what differentiates someone from others,” he says. “You have to earn the credibility and by doing so, you have to make sure you’re well balanced and you’re able to give both sides of the story.” Effective storytelling is about framing evidence in a way that resonates with the audience’s priorities. Academic physicians may want detailed scientific discussions. Frontline clinicians often want practical outcomes such as reduced hospitalizations, improved quality of life, and better patient adherence. Medical affairs leaders who understand these differences are better positioned to influence decisions and strengthen relationships across the healthcare ecosystem. The result is not only stronger engagement but also deeper trust.
The Courage to Protect Scientific Integrity
Trust, however, is not built through communication alone. It is earned through consistent commitment to evidence, especially when that commitment creates tension with business objectives. “Every time you anchor to the patient and the evidence, every time the patient and evidence wins,” he says. “If you lose scientific independence, you’re going to lose credibility.”
He recalls a situation during his tenure as a medical affairs leader when he refused to approve a promotional campaign that lacked adequate scientific support. Despite pressure from senior stakeholders, he declined to sign off. The campaign proceeded without his approval and was ultimately shut down by regulators within days. “The voice that wins is the one that keeps the company out of trouble and keeps physicians trusting you,” Mastoridis says.
Building Strategy Around Real-World Outcomes
As healthcare systems increasingly focus on measurable outcomes, real-world evidence has become a critical strategic asset. “Five years ago, real-world evidence was a nice to have,” he says. “Today it’s the battleground for access, differentiation and credibility.” This evolution requires leaders to think beyond clinical trial endpoints and focus on actual patient behavior, adherence patterns, diagnostic challenges, and healthcare utilization. Payers increasingly want proof that products deliver meaningful outcomes outside controlled study environments.
The same mindset extends to emerging technologies such as AI. Looking ahead, Mastoridis believes future leaders will be defined by their ability to integrate AI and data science into evidence generation while maintaining scientific rigor and patient focus. “The future belongs to medical affairs leaders who are strategic, data literate, digitally literate, and unshakably trustworthy,” he says. In an industry built on evidence, that combination of strategy, storytelling, and trust may be the most valuable leadership asset of all.
Follow Paul Mastoridis on LinkedIn or visit his website for more insights.